SCYNEXIS, Inc. (SCYX)

NASDAQ: SCYX · Delayed Price · USD
4.75
-0.05 (-1.04%)
At close: Jan 26, 2022 4:00 PM
4.76
0.01 (0.21%)
After-hours:Jan 26, 2022 7:01 PM EST

Company Description

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States.

It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections.

The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp.

The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

SCYNEXIS, Inc.
SCYNEXIS Logo
CountryUnited States
Founded1999
IPO DateMay 2, 2014
IndustryPharmaceuticals
SectorHealth Care
Employees38

Contact Details

Address:
1 Evertrust Plz Fl 13
Jersey City, New Jersey 07302-3051
United States
Phone201 884 5485
Websitescynexis.com

Stock Details

Ticker SymbolSCYX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001178253

Key Executives

NamePosition
Dr. Marco Taglietti M.D.Chief Executive Officer, President and Director
David Gonzalez AnguloChief Medical Officer
Lawrence R. Hoffman CPA, Esq.Interim Chief Financial Officer and Principal Accounting Officer
Scott Sukenick J.D.General Counsel and Corporate Secretary
Dr. Rajeshwar MotheramSenior Vice President of Pharmaceutical Development and Supply Chain
Christine R. Coyne M.B.A.Chief Commercial Officer

Latest SEC Filings

DateTypeTitle
Dec 10, 2021SC 13G/AStatement of acquisition of beneficial ownership by individuals
Dec 2, 20213Initial statement of beneficial ownership of securities
Nov 12, 2021SC 13G/AStatement of acquisition of beneficial ownership by individuals
Nov 10, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 10, 20218-KCurrent report
Nov 4, 20218-KCurrent report
Oct 29, 20218-KCurrent report
Sep 17, 2021424B3Prospectus [Rule 424(b)(3)]
Sep 17, 2021424B3Prospectus [Rule 424(b)(3)]
Sep 16, 2021EFFECTNotice of Effectiveness
View All SEC Filings